In Japan pathologists agreed that “relevant genomic biomarker tests for RET-altered lung (32%) and thyroid (23%) cancer are available in their clinical setting,” compared to 63% and 75% in the UK, 95% and 90% in Germany and 77% and 87% in the US (p =  < 0.001). This evidence concerns the gene RET and cancer.